TICKERNERD
Menu
OSRHOSRHHealthcare · Biotechnology

OSRH Stock Forecast: OSR Health, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.27
−8.68% on the day

The 1 Wall Street analysts covering OSR Health, Inc. hold a median 12-month price target of $10 — +3613.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$9.7M
Ticker Nerd rank
24 / 100
Median analyst target
$10
Analysts covering
1
Total return, dividends reinvested
1W
−14.8%
1M
−38.5%
YTD
−52.3%
1Y
−42.9%
From 52W high
−73.3%
From 52W low
0.0%
$0.27
$1.01
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OSRH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores OSR Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
24 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
93
Accruals
71
Growth
65
Momentum
34
Volatility
33
Revisions
25
Quality
19
Issuance
18
Value
8

Size (93): Smaller than most of the companies we track.

Value (8): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OSRH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OSRH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26OSRHHigh $10Median $10Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $10Median $10High $10

The green dot is the last close — the median target sits +3613.3% from it.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OSRH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

OSRH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

OSR Health, Inc. (OSRH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
10.5×

Cheaper than 58% of US stocks

Price / sales
5.4×

Cheaper than 24% of US stocks

Price / book
0.1×

Cheaper than 91% of US stocks

EV / EBITDA
−4.6×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
−72.2%

Higher than 3% of US stocks

Earnings growth (YoY)
−36.4%

Higher than 13% of US stocks

Gross margin
33.1%

Higher than 39% of US stocks

Operating margin
−960.8%

Higher than 5% of US stocks

Net margin
20.4%

Higher than 82% of US stocks

Returns & dividend
Return on equity
−11.3%

Higher than 35% of US stocks

Return on assets
−6.0%

Higher than 30% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

OSRH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OSRHOSR Health, Inc.$9.7M
24
LNAILunai Bioworks, Inc.$9.8M
31
MTVAMetaVia, Inc.$9.6M
17
SKYESkye Bioscience, Inc.$9.8M
34
FBLGFibroBiologics, Inc.$9.6M
47
AEONAEON Biopharma, Inc.$9.6M
48
IMNNImunon, Inc.$9.2M
22

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own OSR Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OSRH news & analysis

OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission

Accesswire · 21 Aug 2026neutral

OSR Health released a letter from its CEO to shareholders outlining its Nasdaq hearing request, its $15 million Put Option, and continued development across its subsidiary pipeline. The company described these steps as preparing its appeal, advancing its catalysts, and continuing its mission.

Why it matters — OSRH watchers would care because the letter addresses the company's Nasdaq appeal process and outlines ongoing operational and financial initiatives that could affect the company's trajectory.

OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal

Accesswire · 19 Aug 2026negative

OSR Health received a written Staff Delisting Determination from the Nasdaq Listing Qualifications Department, notifying that its common stock and warrants are subject to delisting from The Nasdaq Capital Market due to failure to regain compliance with the minimum bid price requirement of Listing Rule 5550(a)(2). The company intends to request a hearing before the Nasdaq Independent Hearings Panel to appeal the determination.

Why it matters — OSRH watchers would care because the company's securities face potential removal from Nasdaq trading, which it now seeks to overturn through its appeal.

OSR Health Sees Global Shareholder Momentum at Critical Inflection Point

Accesswire · 19 Aug 2026positive

OSR Health released a shareholder letter from its CEO citing extraordinary trading activity and global shareholder support at a critical inflection point. The letter reiterates the company's ongoing commitment to Nasdaq compliance and its CVR program.

Why it matters — OSRH watchers would note the CEO's framing of strong shareholder momentum and reaffirmed Nasdaq compliance and CVR commitments during a pivotal period for the company.

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

Accesswire · 11 Aug 2026positive

OSR Health's Founder and CEO issued a letter to shareholders reaffirming confidence and highlighting accelerating subsidiary business development. The letter also addresses the upcoming August 18 practical deadline for Nasdaq's determination regarding the company's continued listing if its stock price does not regain the $1.00 minimum bid requirement by market close.

Why it matters — OSRH watchers would care because the CEO's letter directly addresses the Nasdaq continued-listing deadline, which is a material risk factor for the stock, while also signaling progress in subsidiary growth.

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

Accesswire · 7 Aug 2026neutral

OSR Health issued a clarification to its July 31, 2026 press release concerning Nasdaq and its Shareholder Loyalty CVR Program. The company stated that a quote in the prior release should not be interpreted as Nasdaq having approved or endorsed the program.

Why it matters — OSRH watchers would care because the clarification corrects a potentially misleading impression about the regulatory status of the company's Shareholder Loyalty CVR Program.

FAQ

Frequently asked questions about OSRH stock

What is the OSRH stock price forecast for 2026-2027?

The 1 Wall Street analysts covering OSR Health, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OSRH stock a buy right now?

Of the 1 analysts covering OSR Health, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OSR Health, Inc. 24 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OSRH?

As at 22 Aug 2026, OSR Health, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).

Will OSRH stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +3613.3% from the last close, and Ticker Nerd's factor model ranks OSR Health, Inc. 24 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OSRH stock forecast for 2030?

No analyst covering OSR Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OSRH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $10 over the next 12 months.

How has OSRH stock performed over the past year?

OSR Health, Inc. returned -42.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does OSR Health, Inc. do?

OSR Holdings Inc. is a healthcare holding company operating a hub-and-spoke model with wholly owned subsidiaries focused on advancing biomedical innovations across immuno-oncology, regenerative biologics, noninvasive glucose monitoring, and medical device distribution.

What is the latest news on OSRH?

The most recent item we track (Accesswire, 21 Aug 2026): "OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission". OSR Health released a letter from its CEO to shareholders outlining its Nasdaq hearing request, its $15 million Put Option, and continued development across its subsidiary pipeline. The company described these steps as preparing its appeal, advancing its catalysts, and continuing its mission.

Company

About OSR Health, Inc.

OSR Holdings Inc. is a healthcare holding company operating a hub-and-spoke model with wholly owned subsidiaries focused on advancing biomedical innovations across immuno-oncology, regenerative biologics, noninvasive glucose monitoring, and medical device distribution. Through subsidiaries like Vaximm AG, it develops oral T-cell immunotherapies targeting tumor vasculature, including candidates such as VXM01 for glioblastoma in phase 2 trials, and preclinical products addressing mesothelin, WT1, CEA, and PD-L1. In regenerative biologics, it advances design-augmented assets like DRT-102 for spinal fusion and DRT-101 for osteoarthritis. Woori IO Co., Ltd. pioneers needle-free glucose monitoring using near-infrared spectroscopy technology, while another segment distributes neurovascular intervention systems in South Korea. Headquartered in Bellevue, Washington, with operations in the United States, Switzerland, and South Korea, OSR Holdings Inc. centralizes expertise to support its portfolio, emphasizing simplification through innovation to develop differentiated treatments for cancer, degenerative diseases, diabetes management, and neurovascular conditions.

CEO Mr. Kuk Hyoun Hwang · 22 employees · United States · https://osr-holdings.com